Glynase XL 10 Tablet contains Glipizide 10 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from pancreatic beta cells, thereby lowering blood glucose levels. Glynase XL is formulated as an extended-release tablet, allowing for once-daily dosing to improve patient compliance and maintain more consistent plasma drug concentrations. This medication is prescribed as an adjunct to diet and exercise to achieve optimal glycemic control in adults whose blood glucose levels cannot be adequately controlled by lifestyle modifications alone. It is essential to monitor blood glucose regularly during therapy to adjust dosage and minimize the risk of hypoglycemia, a common adverse effect associated with sulfonylureas. Glynase XL should be used with caution in patients with hepatic or renal impairment, as altered drug metabolism may increase the risk of adverse reactions. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Patients should be educated about recognizing symptoms of hypoglycemia and advised to carry glucose tablets or other sources of rapid-acting sugar. Overall, Glynase XL 10 Tablet is an effective option for improving glycemic control in type 2 diabetes when used as part of a comprehensive treatment plan.